The present invention relates to the use of melatonin for the production of a pharmaceutical composition suitable for intratumoural administration for the treatment of tumours. The composition comprises high concentrations of melatonin, derivatives of melatonin or metabolites, such that the melatonin has an oxidising effect, increasing the production of free radicals and inducing cell death activation.